1. Calmette A and Guerin C: La vaccination preventive contre latuberculose par le “BCG”. Paris Masson 1927; 73: 79. 2. Pearl R: Cancer and tuberculosis. Am J Hygiene 1929; 9: 97. 3. Old LJ, Clarke DA and Benacerraf B: Effect of bacillusCalmette-Guerin infection on transplanted tu...
3. Old LJ, Clarke DA and Benacerraf B: Effect of bacillusCalmette-Guerin infection on transplanted tumours in themouse. Nature 1959; 184: 291. 4. Zbar B, Bernstein ID and Rapp HJ: Suppression of tumorgrowth at the site of infection with living bacillus CalmetteGuerin. J Natl Cancer Inst...
01、關於膀胱癌 膀胱癌的發病率居中國男性泌尿生殖係統惡性腫瘤首位。初診時約75%的原發膀胱癌屬於非肌層浸潤性膀胱癌(non-muscle invasive bladder cancer,NMIBC)。經尿道膀胱腫瘤切除術(transurethral resection of bladder tumor,TURBT)是NM...
2.RATIONALE FOR INTRAVESICAL IFNA2 REPLACEMENT AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM THE NADOFARAGENE FIRADENOVEC PHASE 3 TRIAL 40
3.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).2023ASCO GU. Abstract ...
2. Pearl R: Cancer and tuberculosis. Am J Hygiene 1929; 9: 97. 3. Old LJ, Clarke DA and Benacerraf B: Effect of bacillusCalmette-Guerin infection on transplanted tumours in themouse. Nature 1959; 184: 291. 4. Zbar B, Bernstein ID and Rapp HJ: Suppression of tumorgrowth at the sit...
导语:过去六年来,由于对首选药物卡介苗(BCG)的生产限制导致全球范围内的短缺,治疗非肌层浸润性膀胱癌(NMIBC)患者,我们从下面相关方面回顾卡介苗治疗的现状。美联医邦作为拥有8年海外就医服经验的美国本土出国看病服务机构,本篇为大家分享美国治疗乳腺癌新药Krazatli的讯息。同时分享我们协助国内患者参与美国视频会诊/赴美...
膀胱癌是全球第十大常见癌症,占全球癌症死亡总数的2.1%。膀胱尿路上皮癌约占所有膀胱癌病例的90%。约四分之三的膀胱尿路上皮癌患者存在局限于尿路上皮(Ta期或原位癌)或固有层(T1期)的肿瘤,统称为非肌层浸润性膀胱癌。 大多数高危非肌层浸润性膀胱癌(高级别Ta、原位癌或任何T1)患者的标准治疗是经尿道膀胱肿瘤...
原文出处:ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何...
Over 30 years' successful application of Bacillus Calmette Guerin (BCG) to the clinical treatment of bladder cancer has proved it one of the most promising immunotherapies for cancer. However, the applications and achievements have failed to uncover the mechanism of BCG works on bladder cancer ...